Live data · NADAC + Part D CY24 · reviewed daily

Drospirenone and Ethinyl Estradiol (Jasmiel)

First FDA approval2001-05-11
Generic availableYes · 11 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.149/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.665
Across all dosage forms in distribution.
Highest NADAC
$5.84
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Drospirenone and Ethinyl Estradiol used for?

Drospirenone and Ethinyl Estradiol is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Drospirenone and Ethinyl Estradiol?

Yes. 18 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

How much does my plan pay for Drospirenone and Ethinyl Estradiol?

Across 329 Part D plans, Drospirenone and Ethinyl Estradiol averages $0.665/unit (NADAC). Lowest available: $0.149/unit. Highest in distribution: $5.84/unit.

Is Drospirenone and Ethinyl Estradiol on the FDA shortage list?

Drospirenone and Ethinyl Estradiol has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.